Consensus Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
3.44 ^USD	+4.24%		-5.23%	+132.43%

May. 02	Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02	Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Cardiff Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f432e2db9cfa45838841a00babf.Wsu1bR1x3WE93xMLglBX0YRWjcOijKD-CBx5XRZ01YE.Hr_iJ1ELrFNqlEZAtxU7vbI6xq3U0-7TQ0xAL1RGiuMdoeYXWR3pCmeqfA~89e062094bfbd4c1a65e03b17e3ee77d

Analyst Recommendations on Cardiff Oncology, Inc.

HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	Mar. 06	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	Mar. 01	MT
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Cardiff Oncology to $13 From $14, Maintains Buy Rating	23-08-08	MT
HC Wainwright Trims Cardiff Oncology Price Target to $14 From $15, Maintains Buy Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on Cardiff Oncology to $15 From $14, Keeps Buy Rating	23-03-07	MT
Baird Adjusts Cardiff Oncology's Price Target to $5 From $6, Keeps Outperform Rating	22-09-27	MT
HC Wainwright Adjusts Cardiff Oncology's Price Target to $14 From $22, Reiterates Buy Rating	22-09-16	MT
Piper Sandler Cuts Price Target on Cardiff Oncology to $5 From $7, Retains Overweight Rating	22-09-13	MT
Baird Adjusts Cardiff Oncology's Price Target to $6 From $9, Keeps Outperform Rating	22-08-29	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $20, Reiterates Overweight Rating	22-05-31	MT
Baird Adjusts Price Target on Cardiff Oncology to $9 From $13, Keeps Outperform Rating	22-05-10	MT
HC Wainwright Lowers Cardiff Oncology's Price Target to $22 From $25, Buy Rating Kept	22-05-09	MT
Piper Sandler Adjusts Cardiff Oncology's Price Target to $20 from $25, Keeps Overweight Rating	22-02-28	MT
Maxim Adjusts Cardiff Oncology's Price Target to $9 from $14, Keeps Buy Rating	22-02-28	MT
HC Wainwright Adjusts Cardiff Oncology's Price Target to $25 from $26, Keeps Buy Rating	22-02-28	MT
Maxim Adjusts Cardiff Oncology's Price Target to $14 From $25, Reiterates Buy Rating	22-01-24	MT
William Blair Starts Cardiff Oncology at Outperform	22-01-05	MT
Baird Starts Cardiff Oncology at Outperform With $19 Price Target	21-12-08	MT
Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival	21-09-08	CI
CARDIFF ONCOLOGY : HC Wainwright Adjusts Cardiff Oncology PT to $25 From $27, Maintains Buy Rating	21-05-10	MT